Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, announced today the formation of its
new Scientific Advisory Board (SAB) with appointment of seven
doctors and rheumatology experts. The SAB includes Stanley Cohen,
MD; Andrew Concoff, MD, FACR, CAQSM; Kevin Deane, MD, PhD; Paul J.
DeMarco, MD; Harris Perlman, PhD; Eric Ruderman, MD; and Marina
Sirota, PhD.
“We are thrilled to be able to work with the prestigious group
of scientific thought leaders that we have gathered for our
Scientific Advisory Board. Each member brings with them deep and
expansive experience in the field of rheumatology, with specialized
focus in rheumatoid arthritis,” said Ron Rocca, Exagen’s President
and Chief Executive Officer. “Their insights will provide Exagen
with key and relevant counsel in the continued development and
growth of AVISE® RADR.”
The founding members of the Exagen RA Scientific Advisory Board
are:
Stanley Cohen, M.D. is a Clinical Professor in
the Department of Internal Medicine at UT Southwestern Medical
Center and Co-Director of the Division of Rheumatology at
Presbyterian Hospital, Dallas. He also is Co-Medical Director of
Metroplex Clinical Research Center. Dr. Cohen was honored in 2016
with the designation of Master by the American College of
Rheumatology (ACR) and was awarded the American College of
Rheumatology’s Presidential Gold Medal in 2021 for his outstanding
contributions to the advancement of rheumatology. He is a past
president of the ACR and has extensive experience in RA clinical
trials.
Andrew Concoff, MD, FACR, CAQSM is the
Executive Vice President, Chief Medical Officer at United
Rheumatology. Dr. Concoff previously applied his training as one of
the few doctors in the nation to have completed fellowships in both
Rheumatology and Sports Medicine to his hybrid-specialty private
practice in Southern California. Along with his clinical practice,
he served as Medical Director for Outpatient Rehabilitation,
leading the transition to evidence-driven physical therapy and the
development of a value-based low back pain assessment and treatment
program. Dr. Concoff received a Career Development Award from the
National Institutes of Health for his research in exercise for knee
osteoarthritis.
Kevin Deane, MD, PhD is a Professor of Medicine
in the Division of Rheumatology at the University of Colorado
Anschutz Medical Campus. Dr. Deane is currently a principal or
co-investigator in several multi-centered studies investigating how
genetic, environmental and mucosal factors influence the early
development of RA; he is also an investigator on several clinical
trials in RA including a prevention trial.
Paul J. DeMarco, M.D. is a Board-Certified
Rheumatologist, a Fellow of the American College of Physicians, a
Fellow of the American College of Rheumatology and a member of the
American Institute of Ultrasound in Medicine. Dr. DeMarco served as
Medical Director for the Clinical Trials Department at the
Washington Hospital Center for many years and remains involved in
research. He has published and lectured in most aspects of
rheumatology but has particular interest in connective tissue
diseases in adults and children. He is an Associate Clinical
Professor of Medicine at Georgetown University School of Medicine,
teaching medical students and rheumatology fellows. He is among the
first physicians in the country to achieve certification from the
American College of Rheumatology in Rheumatologic Musculoskeletal
Ultrasonography (RhMSUS).
Harris Perlman, PhD is Chief of Rheumatology
and the Mabel Greene Myers Professor of Medicine and was the
co-senior author of a USA-based study that used genetic profiling
of joint tissue to see which drugs would work for which patients.
Over the past 22 years, his area of interest has centered on
rheumatic disease. His laboratory focuses on using functional
genomics and clinomics towards the development of a precision
medicine approach for the treatment of rheumatoid arthritis (RA)
and systemic sclerosis (SSc). Dr. Perlman has created a central
digital biorepository for peripheral blood, serum and tissues
(synovial biopsy) from RA and SSc (esophageal, skin, BAL) patients.
Single cell populations of immune cells are analyzed from these
biopsies via spatial transcriptomics as well as CITE, RNA and ATAC
seq. Thus, by using the cutting-edge technologies, data has the
potential to be paradigm shifting and transformative to understand
the function of individual populations of monocytes and macrophages
in relationship to developing a precision medicine approach for
patients.
Eric Ruderman, MD is the Associate Chief,
Clinical Affairs for the Division of Rheumatology at Northwestern
University Feinberg School of Medicine. His academic focus links
the clinical and research enterprises within the division to foster
novel translational work that will advance the field of
rheumatology. He is very interested in clinical trial designs and
serves on the data safety monitoring boards for several
multi-center clinical trials. Dr. Ruderman has served as a Vice
Chair in the Northwestern IRB for over 15 years.
Marina Sirota, PhD is an Associate Professor at
the Bakar Computational Health Sciences Institute at UCSF. Her
research interests lie in developing computational integrative
methods and applying these approaches in the context of disease
diagnostics and therapeutics. Her primary focus is on leveraging
and integrating different types of omics and clinical data to
better understand the role of the immune system in disease. The
Sirota laboratory is funded by NIA, NLM, NIAMS, Pfizer, March of
Dimes and the Burroughs Welcome Fund. As a young leader in the
field, she has been awarded the AMIA Young Investigator Award in
2017. Dr. Sirota also is the director of the AI4ALL program at
UCSF, with the goal of introducing high school girls to
applications of AI and machine learning in biomedicine.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis, and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus. For further information please
visit www.exagen.com.
Forward Looking Statements
Exagen cautions you that statements in this press release
regarding matters that are not historical facts are forward-looking
statements. These statements are based on Exagen’s current beliefs
and expectations. Such forward-looking statements include, but are
not limited to, statements regarding the Scientific Advisory
Board’s insight and counsel leading to any potential development of
the AVISE® RADR Platform. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: that developing new molecular signatures involves a
lengthy and complex process, and the collaboration may not lead to
the successful development of related testing products and Exagen
may not be able to commercialize any such products on a timely
basis, or at all; the COVID-19 pandemic may continue to adversely
affect Exagen’s business, financial condition and results of
operations, including as a result of shutdowns of its facilities
and operations as well as those of its suppliers and courier
services, impeding patient movement and interruptions to healthcare
services causing a decrease in test volumes, disruptions to the
supply chain of material needed for its tests, its sales and
commercialization activities and its ability to receive specimens
and perform or deliver the results from its tests, and delays in
ongoing and planned clinical trials involving its tests; Exagen’s
commercial success depends upon attaining and maintaining
significant market acceptance of its testing products and promoted
therapeutics among rheumatologists, patients, third-party payors
and others in the medical community; Exagen’s ability to
successfully execute on its business strategies; third-party payors
not providing coverage and adequate reimbursement for Exagen’s
testing products or promoted therapeutics; Exagen’s ability to
obtain and maintain intellectual property for its testing products;
regulatory developments affecting Exagen’s business; Exagen’s
collaboration and development activities; risks associated with
maintaining the collaboration and license agreements; and other
risks described in Exagen’s prior press releases and Exagen’s
filings with the Securities and Exchange Commission (SEC),
including under the heading “Risk Factors” in Exagen’s Annual
Report on Form 10-K for the year ended December 31, 2020 and any
subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and Exagen undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Investor RelationsExagen Inc. Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2023 to Jul 2024